Decrease Text SizeIncrease Text SizeFacebookTwitterYoutubeInstagramLinkedIn

New defendant in CHEO’s gene patent challenge
Recent developments in CHEO’s gene patent challenge have resulted in a US-based biotechnology company, Transgenomic, purchasing the patents for Long QT genes from the previous defendants.
This means that Transgenomic is the new defendant in the case and that the University of Utah and others have now relinquished their involvement. Back in February, lawyers from the University of Utah informed the courts they wished to settle the matter, whether with Transgenomic or with CHEO.
Transgenomic has since issued a statement informing the Court that the role of the defendant has been transferred to Transgenomic and they will carry out the remainder of the proceeding. CHEO will move forward with the case as planned and will send another update when there is more to communicate.
CHEO originally launched the legal challenge in November as the hospital’s physicians and scientists were concerned that the patenting of human DNA interferes with their ability to continually provide quality care and make full use of genomic technologies as the era of personalized medicine arrives in Canada.
Take Action


 Kids Health Alliance logo

Improving access to coordinated, consistent, high-quality health care for children, youth and their families. 

Quick Links

Programs & Health Info
magnifying glass

Letter aLetter bLetter cLetter eLetter fLetter g Letter hLetter iLetter jLetter kLetter lLetter mLetter nLetter oLetter pLetter qLetter rLetter sLetter t Letter uLetter vLetter wLetter xLetter yLetter z
Zoomed image Close